163 related articles for article (PubMed ID: 31513613)
1. Study on Dalfampridine in the treatment of Multiple Sclerosis Mobility Disability: A meta-analysis.
Shi J; Wu X; Chen Y
PLoS One; 2019; 14(9):e0222288. PubMed ID: 31513613
[TBL] [Abstract][Full Text] [Related]
2. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
Nikfar S; Rahimi R; Abdollahi M
Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
[TBL] [Abstract][Full Text] [Related]
3. Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.
Applebee A; Goodman AD; Mayadev AS; Bethoux F; Goldman MD; Klingler M; Blight AR; Carrazana EJ
Clin Ther; 2015 Dec; 37(12):2780-7. PubMed ID: 26565077
[TBL] [Abstract][Full Text] [Related]
4. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis.
Dunn J; Blight A
Curr Med Res Opin; 2011 Jul; 27(7):1415-23. PubMed ID: 21595605
[TBL] [Abstract][Full Text] [Related]
5. Dalfampridine: a medication to improve walking in patients with multiple sclerosis.
Pikoulas TE; Fuller MA
Ann Pharmacother; 2012; 46(7-8):1010-5. PubMed ID: 22764324
[TBL] [Abstract][Full Text] [Related]
6. Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials.
Zhang E; Tian X; Li R; Chen C; Li M; Ma L; Wei R; Zhou Y; Cui Y
Orphanet J Rare Dis; 2021 Feb; 16(1):87. PubMed ID: 33588903
[TBL] [Abstract][Full Text] [Related]
7. Dalfampridine benefits ambulation but not cognition in multiple sclerosis.
Satchidanand N; Drake A; Smerbeck A; Hojnacki D; Kolb C; Patrick K; Weinstock-Guttman B; Motl R; Benedict RH
Mult Scler; 2020 Jan; 26(1):91-98. PubMed ID: 30566030
[TBL] [Abstract][Full Text] [Related]
8. Effects of 4-aminopyridine on attention and executive functions of patients with multiple sclerosis: Randomized, double-blind, placebo-controlled clinical trial. Preliminary report.
Arreola-Mora C; Silva-Pereyra J; Fernández T; Paredes-Cruz M; Bertado-Cortés B; Grijalva I
Mult Scler Relat Disord; 2019 Feb; 28():117-124. PubMed ID: 30593980
[TBL] [Abstract][Full Text] [Related]
9. Assessment of confirmed urinary tract infection in patients treated with dalfampridine for multiple sclerosis.
Kantor D; Chancellor MB; Snell CW; Henney HR; Rabinowicz AL
Postgrad Med; 2015 Mar; 127(2):218-22. PubMed ID: 25560174
[TBL] [Abstract][Full Text] [Related]
10. Dalfampridine effects on cognition, fatigue, and dexterity.
Korsen M; Kunz R; Schminke U; Runge U; Kohlmann T; Dressel A
Brain Behav; 2017 Jan; 7(1):e00559. PubMed ID: 28127507
[TBL] [Abstract][Full Text] [Related]
11. Assessing dalfampridine efficacy in the physician's office.
Raffel JB; Malik O; Nicholas RS
Mult Scler; 2014 Jan; 20(1):24-6. PubMed ID: 23727943
[TBL] [Abstract][Full Text] [Related]
12. Evaluating dalfampridine for the treatment of relapsing-remitting multiple sclerosis: does it add to the treatment armamentarium?
Foschi M; Lugaresi A
Expert Opin Pharmacother; 2019 Aug; 20(11):1309-1320. PubMed ID: 31237780
[No Abstract] [Full Text] [Related]
13. Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
Hupperts R; Lycke J; Short C; Gasperini C; McNeill M; Medori R; Tofil-Kaluza A; Hovenden M; Mehta LR; Elkins J
Mult Scler; 2016 Feb; 22(2):212-21. PubMed ID: 25921050
[TBL] [Abstract][Full Text] [Related]
14. Therapies for mobility disability in persons with multiple sclerosis.
Baird JF; Sandroff BM; Motl RW
Expert Rev Neurother; 2018 Jun; 18(6):493-502. PubMed ID: 29772185
[TBL] [Abstract][Full Text] [Related]
15. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
16. Dalfampridine in multiple sclerosis.
Goodman AD; Hyland M
Drugs Today (Barc); 2010 Sep; 46(9):635-9. PubMed ID: 20967295
[TBL] [Abstract][Full Text] [Related]
17. Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study.
Cameron MH; Fitzpatrick M; Overs S; Murchison C; Manning J; Whitham R
Mult Scler; 2014 May; 20(6):733-8. PubMed ID: 24099749
[TBL] [Abstract][Full Text] [Related]
18. The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.
Cornblath DR; Bienen EJ; Blight AR
Clin Ther; 2012 May; 34(5):1056-69. PubMed ID: 22497693
[TBL] [Abstract][Full Text] [Related]
19. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
20. Effect of dalfampridine on information processing speed impairment in multiple sclerosis.
De Giglio L; De Luca F; Gurreri F; Ferrante I; Prosperini L; Borriello G; Quartuccio E; Gasperini C; Pozzilli C
Neurology; 2019 Aug; 93(8):e733-e746. PubMed ID: 31331968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
